Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway AnalysisGlobe News Wire · Oct 12, 2026
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google CloudGlobeNewsWire · Oct 7, 2026
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory BoardGlobeNewsWire · Sep 24, 2026
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug DiscoveryGlobeNewsWire · Sep 23, 2026
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery CampaignGlobeNewsWire · Jul 28, 2026Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | – | -$25.96 | |
| May 14, 2026 | – | -$12.10 | |
| Nov 13, 2025 | – | -$8.29 | |
| Nov 14, 2024 | – | -$12.91 | |
| Aug 14, 2024 | – | -$7.86 | |
| May 15, 2024 | – | -$9.10 |